Telix Pharmaceuticals Limited announced the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 2025. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC and is Chair at QurAlis Corporation. Ms. Whitaker is an accomplished C-suite leader, most recently as Chair and CEO of Aerami Therapeutics Holdings Inc. During her executive career she has held senior leadership roles at GlaxoSmithKline (GSK), Sanofi and Bausch Health. Ms. Whitaker holds a Bachelor of Science in
Chemistry and Business from the University of North Alabama.
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Its segments include commercial, product development, medical technologies, and manufacturing services. Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX101, TLX300, TLX66, TLX66-CDx, and TLX090, among others.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
